Lexicon Pharmaceuticals’ (LXRX) “Hold” Rating Reiterated at Needham & Company LLC

Lexicon Pharmaceuticals (NASDAQ:LXRX)‘s stock had its “hold” rating reiterated by Needham & Company LLC in a report released on Thursday, Benzinga reports.

Lexicon Pharmaceuticals Stock Performance

Shares of LXRX opened at $1.97 on Thursday. The company has a 50-day simple moving average of $2.42 and a 200-day simple moving average of $1.68. The company has a quick ratio of 5.58, a current ratio of 5.60 and a debt-to-equity ratio of 1.07. Lexicon Pharmaceuticals has a 52 week low of $0.92 and a 52 week high of $3.79.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Monday, March 11th. The biopharmaceutical company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.03. The business had revenue of $0.70 million during the quarter, compared to analyst estimates of $0.68 million. Lexicon Pharmaceuticals had a negative net margin of 14,573.20% and a negative return on equity of 138.54%. On average, equities research analysts forecast that Lexicon Pharmaceuticals will post -0.71 EPS for the current fiscal year.

Institutional Trading of Lexicon Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LXRX. Cantor Fitzgerald L. P. bought a new stake in Lexicon Pharmaceuticals in the fourth quarter valued at about $25,000. Bank of Montreal Can bought a new stake in Lexicon Pharmaceuticals in the first quarter valued at about $26,000. Baystate Wealth Management LLC bought a new stake in Lexicon Pharmaceuticals in the second quarter valued at about $28,000. TIAA Trust National Association bought a new stake in Lexicon Pharmaceuticals in the third quarter valued at about $29,000. Finally, Principal Securities Inc. bought a new stake in Lexicon Pharmaceuticals in the fourth quarter valued at about $33,000. Institutional investors own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.